TrialReader

Survival Outcomes of Ovarian Malignancies in Chinese Population

NCT03291262 — Unknown, 5000 participants, Lei Li
ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT03291262
StatusUnknown
Study typeObservational
Enrollment5000 (Estimated)
SponsorLei Li (Other)
ConditionsOvarian Neoplasms, Survival
InterventionsFollow up for death and recurrence (Other)
Datesstart 2017-01-01, primary completion 2022-01-01 (estimated), completion 2023-01-01 (estimated), first posted 2017-09-25, last updated 2018-11-14
Locations1 site in China

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Ovarian Neoplasms All trials for Survival All trials of Follow up for death and recurrence

-Summary

This study aims to determine survival outcomes (overall survival and progression-free survival) of primary ovarian malignancies in China and relevant risk factors in a prospective cohort study.

Expand all sections  ·  Collapse all

+Arms and interventions

  • Follow up for death and recurrence (Other): Patients are followed up to determine the specific date of diagnosis, recurrence and death.

+Outcome measures

Primary outcomes

  • Overall survival [5 years]: Periods from diagnosis of ovarian cancer to death
  • Progression-free survival [5 years]: Periods from diagnosis of ovarian cancer or remission of disease to next recurrence

+Eligibility

Sex: Female

Inclusion Criteria:

* Primary ovarian malignancies.

Exclusion Criteria:

* Metastatic malignancies to ovaries.

+Locations (1)

FacilityCityCountryStatus
Lei LiBeijing, China/BeiingChinaRecruiting

+Publications

  • Results publication: Sun T, Li L. A cohort study of hypersensitivity reaction in patients with epithelial ovarian cancer treated with carboplatin. Int J Gynecol Cancer. 2019 Mar;29(3):566-571. doi: 10.1136/ijgc-2018-000072. Epub 2018 Dec 22. PMID 30833442

+Investigators

  • Lei Li, MD, Principal investigator, Peking Union Medical College Hospital

My Notes